Clinical Trials Directory

Trials / Completed

CompletedNCT00214630

LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes

A 12-week Randomized, Open-label 3-arm, Parallel Group, Multicenter Phase IIIb Study Comparing Efficacy and Safety of Rosuvastatin 20mg and 40mg With That of Atorvastatin 80 mg in Subjects With Acute Coronary Syndromes

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
825 (actual)
Sponsor
AstraZeneca · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes

Conditions

Interventions

TypeNameDescription
DRUGrosuvastatin calcium
DRUGatorvastatin

Timeline

Start date
2003-12-01
Primary completion
2007-08-01
Completion
2007-08-01
First posted
2005-09-22
Last updated
2010-11-19

Locations

56 sites across 5 countries: United States, Costa Rica, El Salvador, Morocco, Panama

Source: ClinicalTrials.gov record NCT00214630. Inclusion in this directory is not an endorsement.

LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes (NCT00214630) · Clinical Trials Directory